People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Machinima Inc | — | Other | Series B | $65.5M | $207.7M | 2009 |
| Onconetix, Inc. | — | Biotechnology | Series A | $22.0M | $37.7M | 2024 |
Karina Fedasz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Karina Fedasz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Terbeek | 1 | 18 |
| Allen DeBevoise | 1 | 14 |
| James Sapirstein | 1 | 7 |
| Bret Maxwell | 1 | 6 |
| Geoffrey Yang | 1 | 6 |
| Daniel Murray | 1 | 6 |
| Ajit Singh | 1 | 5 |
| Matt Coffin | 1 | 5 |
| Joi Ito | 1 | 4 |
| Chris Riley | 1 | 3 |
| Yair Landau | 1 | 3 |
| Patricia White | 1 | 2 |
| Stephen Semprevivo | 1 | 1 |
| Philip Debevoise | 1 | 1 |
| Chad Gutstein | 1 | 1 |
| Anthony Vinciquerra | 1 | 1 |
| Simon Tarsh | 1 | 1 |
| Andrew Oakley | 1 | 1 |
| Timothy Ramdeen | 1 | 1 |
| Thomas Meier | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.